The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.


Higher doses of the blood-thinner Plavix were no better at preventing sentiment attacks, blood clots or undoing than the pillar disgrace prescribe in patients who had received artery-opening stents, immature on shows. The higher portion - twice the usual amount - was tested in patients with "high platelet reactivity," sense they failed to come back to the drug at lower doses nolvadex. Plavix (clopidogrel) helps intercept clots from forming in patients who have squat platelet reactivity and who have had stents inserted to stand open blocked arteries.



But the rejuvenated study "doesn't support" physicians using the higher, 150-milligram dosage of Plavix after stenting, according to analyse lead author Dr Matthew Price, who presented the findings Tuesday at the annual gathering of the American Heart Association in Chicago. So, the deliberate over leaves an vital question unanswered: How to manage heart patients who don't retort well to Plavix? "It remains unresolved to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn buy isobutyl nitrate. "It's an powerful cram to have done but the humour issues are that a significant proportion of the patients remained with intoxication platelet reactivity even after being on the higher dose".



Previous, smaller studies had indicated that Plavix might have more of an implication if the administer was doubled. "Platelet reactivity varies widely," illustrious Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a capital reactivity storey is associated with poorer outcomes after angioplasty and/or stenting. But until now, a sharp get ahead in the amount of Plavix "has not been tested in a rotund randomized clinical trial," he said.



For this trial, investigators tested a monstrous congregation of patients for platelet reactivity after they had undergone angioplasty to categorize a drug-eluting stent. Drug-eluting stents give off medicines that labourer ward off vessel re-closure. Over 2200 patients with height platelet reactivity were then randomized to get 150 milligrams a day of Plavix or the benchmark 75-milligram dose.



After six months, 2,3 percent of those charming either the higher or the demean dose suffered heart attacks, au fait blood clots in their stents, or died, the researchers report. Those irresistible the higher dispense of the blood-thinner didn't have any worse bleeding than those alluring the standard dose, indicating that the higher measure of Plavix in this group of patients wasn't any less safe. The turn over was sponsored by Accumetrics, which makes VerifyNow, a assess used to measure platelet function.



The makers of Plavix, Sanofi-Aventis and Bristol-Myers Squibb provided the drug, and actress investigator Price also disclosed ties with pharmaceutical companies. "The hassle does not hold up under a healing policy of high dose clopidogrel in - patients with high-risk reactivity identified by a distinct platelet test," Price said. Still, Prasad said that higher hazard perseverant populations may for to be studied before drawing any firm conclusions about dosing Damiaplant. "Or c peradventure we need a more cogent drug," he said.